Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing DrugInvestors Business Daily • 11/16/23
Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicineMarket Watch • 11/16/23
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.The Motley Fool • 11/16/23
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 11/16/23
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving AverageZacks Investment Research • 11/07/23
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/06/23
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023GlobeNewsWire • 11/06/23
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDAThe Motley Fool • 11/03/23